Activity content starts in:
Industry Webcast
A Treatment Option for Patients With Uncontrolled Moderate-to-Severe Atopic DermatitisIndustry Webcast Sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.; Not for CME/CE Credit
Learn more about a treatment option that may help appropriate patients with uncontrolled moderate-to-severe atopic dermatitis (AD).
CME/CE Information
0 Credits - Not for CME/CE Credit
Release Date: 2/20/2025
Expiration Date: 2/20/2025
Topics
Faculty
Faculty
Cory Rubin, MD, FAAD
Assistant Professor, Dermatology
Oakland University William Beaumont School of Medicine
Rochester, Michigan
Supporters and Partners
Industry Sponsor
Sanofi
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.